A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)

Clinical trial NCT00894114 · COMPLETED

Trial details

NCT number: NCT00894114
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

HIV-1 Infection

Start date: 2003-05-01
Primary completion: 2009-06-01
Enrollment: 250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.